Contract Manufacturing Services

Catalent to Manufacture J&J’s Lead COVID-19 Vaccine Candidate

April 30, 2020

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Wavelength Pharmaceuticals Expands Supplies of Drug Ingredients for Managing COVID-19 and Adds API CDMO Services

April 23, 2020

Wavelength Pharmaceuticals expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients in the COVID-19 pandemic.

Catalent Expands Biologics Packaging Capacity

April 23, 2020

Catalent Biologics increased capacity at its Bloomington, IN Facility.

MilliporeSigma Adds Viral Vector and Gene Therapy Capacity

April 21, 2020

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.

Addressing Drug Shortages

April 15, 2020

Equipment and Processing Report

Civica Rx plans redundant manufacturing capacity to relieve and prevent shortages of generic, sterile injectable drugs.

Avoiding Negative Drug–Device Interactions

April 02, 2020

Considering the potential interaction of a drug with the delivery device early on in in development is integral to achieving the best combination.

Delivering the Goods

April 02, 2020

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Addressing Drug Shortages

April 02, 2020

Civica Rx plans redundant manufacturing capacity to relieve and prevent shortages of generic, sterile injectable drugs.

iBio Advances COVID-19 Vaccine Development

March 30, 2020

Pre-clinical immunization studies of iBio’s SARS-CoV-2 VLP candidates are being performed by Texas A&M.

iBio Supports AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

March 28, 2020

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.